BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.35 -0.40 (-0.72%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims

October 26, 2021

NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

From Jakubowitz Law

Via AccessWire

Topics Fraud Lawsuit

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 26, 2021

From The Schall Law Firm

Via Business Wire

CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

October 26, 2021

NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....

From Levi & Korsinsky, LLP

Via AccessWire

Topics Initial Public Offering Lawsuit

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

October 26, 2021

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN

October 26, 2021

NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to...

From The Klein Law Firm

Via AccessWire

Topics Fraud Intellectual Property

SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

October 26, 2021

NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...

From The Law Offices of Vincent Wong

Via AccessWire

Topics Fraud Intellectual Property Lawsuit

Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims

October 25, 2021

NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

From Jakubowitz Law

Via AccessWire

Topics Fraud Lawsuit

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN

October 25, 2021

From Rosen Law Firm

Via Business Wire

Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More ↗

October 16, 2021

This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc. ↗

September 22, 2021

San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug ↗

September 09, 2021

Stifel

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗

September 09, 2021

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:

Via Benzinga

Price To Earnings Ratio Insights For Biomarin Pharmaceutical ↗

September 07, 2021

In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 07, 2021

Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...

Via Benzinga

FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder ↗

September 07, 2021

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene...

Via Benzinga

Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval ↗

August 27, 2021

The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The...

Via Benzinga

Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months ↗

August 20, 2021

All it will take is an FDA approval and a partial repeat of history.

Via The Motley Fool

BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗

July 29, 2021

BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,...

Via Talk Markets

BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance ↗

July 29, 2021

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to...

Via Benzinga

BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript ↗

July 29, 2021

BMRN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Biomarin Pharmaceutical: Q2 Earnings Insights ↗

July 28, 2021

Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the...

Via Benzinga

BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy ↗

July 21, 2021

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy...

Via Benzinga

BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22 ↗

July 15, 2021

The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene...

Via Benzinga

EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate ↗

June 25, 2021

European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of BioMarin...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy ↗

May 24, 2021

The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc’s (NASDAQ: BMRN)...

Via Benzinga

Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit ↗

May 19, 2021

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an...

Via Benzinga

Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript ↗

April 29, 2021

BMRN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.